 |
|
|
| |
Effect of CCL3L1 Copy Number Variation on CD4+ Cell Recovery in Treatment-Naïve Patients: 96-Week Results from the Maraviroc in Treatment-Naïve Patients (MERIT) Study
|
| |
| |
Reported by Jules Levin
CROI 2010 Feb 16-19 SF
Xiaolan Hu1, Stephanie Hall1, Jeremy Wheeler2, Craig Hyde1, Frances Sanders3, Philip Rowe2, James Goodrich4, Howard Mayer5, Hernan Valdez6
1Pfizer Global Research and Development, New London, CT, USA; 2Quanticate Ltd, Hitchin, UK; 3Pfizer Global Research and Development, Sandwich, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5EMD Serono, Inc, Rockland, MA, USA; 6Pfizer Inc, New York, NY, USA
|
| |
|
|
|
|
|
